Navigation Links
Penn Medicine team reports on study of first 59 leukemia patients who received cell therapy
Date:12/7/2013

ew cells for each single engineered cell patients receive. Cells in the patient that do not express CD19 are left untouched by the modified T cells, which limits the prolonged, systemic side effects typically experienced during traditional cancer therapies that harm healthy tissue.

Treatment Prompts High Response Rates, Durable Remissions

Taken together, the newly announced results show promise for a range of tough-to-treat blood cancers. All study patients had exhausted conventional treatment options. In many cases, they were ineligible for bone marrow transplantation or declined that option due to the risks associated with the procedure, which carries at least a 20 percent mortality risk.

"We are tremendously excited about these results. About half of our CLL patients responded to this therapy, with most of them having several pounds of tumors eradicated by the genetically modified T cells," says study author David L. Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in Penn's Abramson Cancer Center, who will present the two CLL trial abstracts during the meeting. "We've now seen remissions lasting for more than three years, and there are clues that the T cells continue to kill leukemia cells in the body for months after treatment: Even in patients who had only a partial response, we often found that all cancer cells disappeared from their blood and bone marrow, and their lymph nodes continued to shrink over time. In some cases, we have seen partial responses convert to complete remissions over several months."

The research team is especially encouraged by the early results among ALL patients, since that disease progresses rapidly and is very deadly among those who relapse after standard treatments. About 85 percent of pediatric patients with the disease are cured with first-line therapies, but those whose cancers relapse and/or become refractory ha
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. Singapore joins global translational medicine network as Asia-Pacific hub
2. Penn Dental Medicine team identifies molecule critical to healing wounds
3. Sons of cocaine-using fathers may resist addiction to drug, Penn Medicine study suggests
4. Osteoarthritis medicine delivered on-demand
5. College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases
6. Ludwig scientist Richard D. Kolodner elected to the Institute of Medicine
7. Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicines 2013 Lienhard Award
8. Institute of Medicine Elects 70 New Members, 10 Foreign Associates
9. Carnegie Mellon President Subra Suresh elected to Institute of Medicine
10. Institute of Medicine honors members for outstanding service
11. Wyss Institute core faculty member elected to the Institute of Medicine of the National Academies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penn Medicine team reports on study of first 59 leukemia patients who received cell therapy
(Date:7/9/2014)... cooks are turning to more healthful alternatives to their ... sometimes mean low satisfaction. Now researchers are reporting new ... that are made with olive oil rather than pork ... of Agricultural and Food Chemistry . , Ana M. ... to expect just the right amount of chewiness and ...
(Date:7/9/2014)... sparrow-sized fossil from China challenges the commonly held belief ... the ability to fly. The birdlike fossil is actually ... the remains of a tiny tree-climbing animal that could ... Museum in Blanding, Utah, and Alan Feduccia of the ... Journal of Ornithology . , The fossil of ...
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
Breaking Biology News(10 mins):Researchers declassify dinosaurs as being the great-great-grandparents of birds 2First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... Elsevier, a world-leading provider of scientific, technical and ... a new, international, open access journal, Case Studies ... Studies in Engineering Failure Analysis provides a forum ... Studies in Engineering Failure Analysis and will form ...
... of several of the most external atomic layers of ... Analysis by a number of modern techniques. Just opened ... Academy of Sciences, Warsaw, Poland, the Centre provides a ... electron microscope and specialised spectroscopic equipment for surface studies ...
... PHOENIX, Nov. 26, 2012 Webcast AdvisoryWhat:Announcement of a ... internationally respected team racing to unlock genomic codes ... lead to biomedical breakthroughs that will give new ... diagnoses.Who:Phoenix Children,s Hospital, in collaboration with Translational Genomics ...
Cached Biology News:Elsevier launches new open access journal -- 'Case Studies in Engineering Failure Analysis' 2Surface analysis techniques for advanced materials enhance Mazovia's research potential 2Surface analysis techniques for advanced materials enhance Mazovia's research potential 3
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® ... lab, from fluid handling to instruments to supplies. Many ... you order. , Preferred Solutions features a full ... L/S® model for precise flow control and dispensing to ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... everyone has heard of identity theft (IDT), yet unless you ... at high risk. An alarming figure is that over half ... a place of business, employer, or other entity (not-for-profit or ... individuals are required under one or more federal and state ...
... American angel investors continue to be the largest source of ... in the first half of 2006, an increase of 15 ... Center for Venture Research at the University of New ... research on the angel market since 1980, reported that healthcare ...
... had a crystal ball that could help him predict the ... president and research fellow at Yahoo , has a ... called "the cash cow with a big target on it." ... user-generated content (combined with search) that will somehow enable professionals ...
Cached Biology Technology:Identity theft: The business time bomb 2Identity theft: The business time bomb 3Identity theft: The business time bomb 4Angel investors commit $12.7B in first half of `06 2Online communities may be next business market 2Online communities may be next business market 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Biology Products: